| Literature DB >> 31964407 |
Xing Tang1, Xiaopan Xu2, Zhiping Han3, Guoyan Bai4, Hong Wang1, Yang Liu2, Peng Du2, Zhengrong Liang5, Jian Zhang6, Hongbing Lu7, Hong Yin8.
Abstract
BACKGROUND: Non-invasive discrimination between lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) subtypes of non-small-cell lung cancer (NSCLC) could be very beneficial to the patients unfit for the invasive diagnostic procedures. The aim of this study was to investigate the feasibility of utilizing the multimodal magnetic resonance imaging (MRI) radiomics and clinical features in classifying NSCLC. This retrospective study involved 148 eligible patients with postoperative pathologically confirmed NSCLC. The study was conducted in three steps: (1) feature extraction was performed using the online freely available package with the multimodal MRI data; (2) feature selection was performed using the Student's t test and support vector machine (SVM)-based recursive feature elimination method with the training cohort (n = 100), and the performance of these selected features was evaluated using both the training and the validation cohorts (n = 48) with a non-linear SVM classifier; (3) a Radscore model was then generated using logistic regression algorithm; (4) Integrating the Radscore with the semantic clinical features, a radiomics-clinical nomogram was developed, and its overall performance was evaluated with both cohorts.Entities:
Keywords: Clinical features; Lung adenocarcinoma; Lung squamous cell carcinoma; Multimodal MRI radiomics features; Nomogram; Non-small-cell lung cancer
Year: 2020 PMID: 31964407 PMCID: PMC6975040 DOI: 10.1186/s12938-019-0744-0
Source DB: PubMed Journal: Biomed Eng Online ISSN: 1475-925X Impact factor: 2.819
Baseline demographics of the patients involved in this research
| Characteristics | Training cohort | Validation cohort | |
|---|---|---|---|
| Age, years | 0.055 | ||
| Median [range] | 58 [20, 76] | 61 [42, 83] | |
| Sex, no. (%) | 0.220 | ||
| Male | 79/100 (79%) | 33/48 (68.75%) | |
| Female | 21/100 (21%) | 15/48 (31.25%) | |
| Smoking, no. (%) | 0.707 | ||
| Yes | 70/100 (70%) | 32/48 (66.7%) | |
| No | 30/100 (30%) | 16/48 (33.3%) | |
| Side, no. (%) | 0.389 | ||
| Upper left lobe | 34/100 (34%) | 12/48 (25%) | |
| Lower left lobe | 14/100 (14%) | 8/48 (16.7%) | |
| Upper right lobe | 22/100 (22%) | 12/48 (25%) | |
| Middle right lobe | 4/100 (4%) | 2/48 (4.2%) | |
| Lower right lobe | 26/100 (26%) | 14/48 (29.1%) | |
| Location, no. (%) | 0.216 | ||
| Peripheral | 63/100 (63%) | 25/48 (52.1%) | |
| Central | 37/100 (37%) | 23/48 (47.9%) | |
| LD, mma | 0.230 | ||
| Median [range] | 54 [10, 115] | 43.5 [15, 100] | |
| LPD, mma | 0.838 | ||
| Median [range] | 36.5 [8, 77] | 35 [11, 90] | |
| CEA, (ng/ml)a | 0.380 | ||
| Median [range] | 4.7 [0.486, 1135] | 7.11 [1.19, 646.4] | |
| Histological subtype, no. (%) | 0.164 | ||
| Squamous cell carcinoma | 50/100 (50%) | 18/48 (37.5%) | |
| Adenocarcinoma | 50/100 (50%) | 30/48 (62.5%) |
aLD, LPD and CEA indicate the longest diameter, the longest perpendicular diameter, and carcinoembryonic antigen, respectively
Fig. 1Optimal features selection process and their classification performance with both cohorts: a features selection process (AUC indicates the area under the curve of the receiver operating characteristic); b the performance of the selected features in the training cohort; c the performance of the features with the validation cohort
Fig. 2generation and its inter-group distribution (ADC, DWI, T2WI, CM, RLM, GLSZM and GL represent the apparent diffusion coefficient, the diffusion-weighted images, the T2-weighted images, the co-occurrence matrices, the run length matrix, the gray-level size zone matrix, the gray level, respectively): a coefficient map of the 13 features; b sum absolute coefficients of the features with different modalities or categories; c the distribution and inter-group analyses of the
Univariate and multivariable regression analyses of the Radscore with primary clinical features for the histological subtype prediction of NSCLC in the training cohort
| Indicators | Univariate analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| ORa | 95% CI | OR | 95% CI | |||||
| Lower | Upper | Lower | Upper | |||||
| Age | ||||||||
| Sex | 0.413 | 0.015 | 10.889 | 0.59 | ||||
| Smoking | ||||||||
| Side | 0.353 | 0.127 | 0.981 | 0.051 | – | – | – | – |
| Location | 2.191 | 0.954 | 5.028 | 0.06 | – | – | – | – |
| LDa | ||||||||
| LPDa | ||||||||
| CEAa | 0.661 | 0.488 | 1.129 | 0.062 | ||||
The underlined values indicate statistical significance with p value < 0.05 after the univariate analysis
The italics underlined values indicate statistical significance with p value < 0.05 after the multivariable analysis
aLD, LPD, CEA and OR indicate the longest diameter, the longest perpendicular diameter, carcinoembryonic antigen, and odds ratio, respectively
Fig. 3Construction and validation of the nomogram: a development of the nomogram based on the and independent clinical predictors (LD and LPD represent the longest diameter and the longest perpendicular diameter, respectively); b the risk calculated and its statistical inter-group distribution differences; c performance verification (AUC indicates the area under the curve of the receiver operating characteristic)
Performance of the radiomics–clinical nomogram in discriminating between lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) in both training and validation cohorts
| Cohort | Sena | Spea | Acca | AUCa | 95% CI | ||
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| Training | 90.0% | 76.0% | 83.0% | 0.901 | 0.842 | 0.960 | < 0.05 |
| Validation | 88.9% | 73.3% | 79.2% | 0.872 | 0.779 | 0.965 | < 0.05 |
aSen, Spe, Acc and AUC indicate the sensitivity, specificity, accuracy and area under the curve of the receiver operating characteristic curve, respectively
Fig. 4Clinical usefulness assessed by using the decision curve analysis indicating a greater net benefit than individually using the clinical model or the radiomics model
Fig. 5The overall schematic outline of this study for the preoperative discrimination between squamous cell carcinoma (LUSC) and adenocarcinoma (LUAD)
Fig. 6Inclusion and exclusion criteria of this study (LUSC and LUAD represent the lung squamous cell carcinoma and lung adenocarcinoma, respectively)
Fig. 7Examples of the delineated lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) on the multimodal MRI data